Contrasting Guided Therapeutics (GTHP) and Its Competitors

Guided Therapeutics (OTCMKTS:GTHP) is one of 78 public companies in the “Electromedical equipment” industry, but how does it contrast to its competitors? We will compare Guided Therapeutics to related companies based on the strength of its risk, institutional ownership, analyst recommendations, dividends, profitability, earnings and valuation.

Earnings and Valuation

This table compares Guided Therapeutics and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Guided Therapeutics	$100,000.00	-$3.49 million	-5.33
Guided Therapeutics Competitors	$974.06 million	$81.52 million	9.84

Guided Therapeutics’ competitors have higher revenue and earnings than Guided Therapeutics. Guided Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

9.7% of Guided Therapeutics shares are held by institutional investors. Comparatively, 44.3% of shares of all “Electromedical equipment” companies are held by institutional investors. 66.8% of Guided Therapeutics shares are held by insiders. Comparatively, 15.1% of shares of all “Electromedical equipment” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Guided Therapeutics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guided Therapeutics	0	0	0	0	N/A
Guided Therapeutics Competitors	287	826	2136	109	2.62

As a group, “Electromedical equipment” companies have a potential upside of 2,878.01%. Given Guided Therapeutics’ competitors higher probable upside, analysts clearly believe Guided Therapeutics has less favorable growth aspects than its competitors.

Profitability

This table compares Guided Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Guided Therapeutics	N/A	N/A	-138.23%
Guided Therapeutics Competitors	-299.08%	-83.96%	-27.59%

Volatility & Risk

Guided Therapeutics has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Guided Therapeutics’ competitors have a beta of 0.92, suggesting that their average stock price is 8% less volatile than the S&P 500.

Summary

Guided Therapeutics competitors beat Guided Therapeutics on 7 of the 10 factors compared.

Guided Therapeutics Company Profile

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.